Management of the polyallergic patient with allergy immunotherapy: a practice-based approach

Allergy, Asthma & Clinical Immunology

Pascal Demoly³  Giovanni Passalacqua²  Oliver Pfaar¹  Joaquin Sastre⁵  Ulrich Wahn⁴ 

[1] Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty Mannheim, Universitatsmedizin Mannheim, Heidelberg University, Mannheim, Germany

[2] Allergy and Respiratory Diseases, IRCCS San Martino-IST, University of Genoa, Genoa, Italy

[3] Sorbonne Universités, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, Paris, France

[4] Department of Paediatric Pulmonology and Immunology, Charité Virchow-Klinikum, Humboldt University, Berlin, Germany

[5] Allergy Division, Fundación Jimenez Díaz, Madrid, Spain

关键词: Polyallergy, polysensitization, multi-allergen, single-allergen practice;    Allergy;    Allergen immunotherapy;   

Others  :  1235365
DOI  :  10.1186/s13223-015-0109-6

 received in 2015-10-23, accepted in 2015-12-22,  发布年份 2016

【 授权许可】

   
2015 Demoly et al.

【 参考文献 】

• [1]Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy. 2005; 60:350-353.
• [2]Bousquet J, Van CP, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001; 108:S147-S334.
• [3]Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al.. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008; 63:S8-S160.
• [4]Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB et al.. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126:466-476.
• [5]Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R et al.. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy. 2009; 64 Suppl 91:1-59.
• [6]Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S et al.. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014; 7:6. BioMed Central Full Text
• [7]Bousquet PJ, Castelli C, Daures JP, Heinrich J, Hooper R, Sunyer J et al.. Assessment of allergen sensitization in a general population-based survey (European Community Respiratory Health Survey I). Ann Epidemiol. 2010; 20:797-803.
• [8]Arbes SJ, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005; 116:377-383.
• [9]Craig TJ, King TS, Lemanske RF, Wechsler ME, Icitovic N, Zimmerman RR et al.. Aeroallergen sensitization correlates with PC(20) and exhaled nitric oxide in subjects with mild-to-moderate asthma. J Allergy Clin Immunol. 2008; 121:671-677.
• [10]Worm M, Lee HH, Kostev K. Prevalence and treatment profile of patients with grass pollen and house dust mite allergy. J Dtsch Dermatol Ges. 2013; 11(7):653-661.
• [11]Migueres M, Fontaine JF, Haddad T, Grosclaude M, Saint-Martin F, Bem David D et al.. Characteristics of patients with respiratory allergy in France and factors influencing immunotherapy prescription: a prospective observational study (REALIS). Int J Immunopathol Pharmacol. 2011; 24(2):387-400.
• [12]Didier A, Chartier A, Démonet G. Immunothérapie sublinguale : pour quel profil de patients en pratique ? Analyse intermédiaire d’Odissee (observatoire de l’indication, du choix de prise en charge par immunothérapie spécifique sublinguale ainsi que de l’adhésion et de l’observance au traitement chez les patients souffrant d’allergie respiratoire [rhinite et/ou conjonctivite et/ou asthme allergique]) = Specific sublingual immunotherapy: for which profiles of patients in practice? Midterm analysis of ODISSEE (observatory of the indication and management of respiratory allergies [rhinitis and/or conjunctivitis and/or allergic asthma] by specific sublingual immunotherapy). Revue Française d’Allergologie. 2010; 50:426-433.
• [13]Didier A, Chartier A, Démonet G. Immunothérapie spécifique sublinguale : ODISSEE un an après. Résultats préliminaires d’ODISSEE (Observatoire de l’indication, du choix de prise en charge par Immunothérapie spécifique sublinguale ainsi que de l’adhésion et de l’observance au traitement chez les patients souffrant d’allergie respiratoire—rhinite et/ou conjonctivite et/ou asthme allergique) = Specific sublingual Immunotherapy: ODISSEE after one year. Preliminary results of ODISSEE (observatory of the indication and management of respiratory allergies rhinitis and/or conjunctivitis and/or allergic asthma by specific sublingual immunotherapy). Revue Française d’Allergologie 2011;51:476–84.
• [14]Langen U. Asthma and sensitization pattern in Children. In: Pereira C, editor. Allergic diseases—highlights in the clinic, mechanisms and treatment. ISBN: 978-953-51-0227-4. Rijeka, Croatia: InTech. 2012. http://www. intechopen.com/books/allergic-diseases-highlights-in-the-clinic-mechanisms-andtreatment/asthma-and-sensitization-pattern-in-children webcite
• [15]Illi S, von Mutius E, Lau S, Niggemann B, Grüber C, Wahn U. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet. 2006; 368(9537):763-770.
• [16]Custovic A, Sonntag HJ, Buchan IE, Belgrave D, Simpson A, Prosperi MC. Evolution pathways of IgE responses to grass and mite allergens throughout childhood. J Allergy Clin Immunol. 2015;136(6):1645–52.e8.
• [17]Simpson A, Lazic N, Belgrave DC, Johnson P, Bishop C, et al. Patterns of IgE responses to multiple allergen components and clinical symptoms at age 11 years. J Allergy Clin Immunol. 2015;136(5):1224–31.
• [18]Westman M, Lupinek C, Bousquet J, Andersson N, Pahr S, Baar A, et al. Mechanisms for the development of allergies consortium. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence. J Allergy Clin Immunol. 2015;135:1199–206.e1-11.
• [19]Ciprandi G, Alesina R, Ariano R, Aurnia P, Borrelli P, Cadario G et al.. Characteristics of patients with allergic polysensitization: the POLISMAIL study. Eur Ann Allergy Clin Immunol. 2008; 40(3):77-83.
• [20]Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W et al.. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015; 136:556-568.
• [21]Cox L, Nelson H, Lockey R, Calabria C, Chacko T et al.. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011; 127(1 Suppl):S1-S55.
• [22]Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol. 2009; 103:451-459.
• [23]Zuberbier T, Bachert C, Bousquet PJ, Passalacqua G, Canonica W, Merk H et al.. GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010; 65:1525-1530.
• [24]Calderón MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol. 2012; 129:929-934.
• [25]Migueres M, Dávila I, Frati F, Azpeitia A, Jeanpetit Y, Lhéritier-Barrand M et al.. Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease. Clin Transl Allergy. 2014; 4:16. BioMed Central Full Text
• [26]Ciprandi G, Cirillo I. Monosensitization and polysensitization in allergic rhinitis. Eur J Intern Med. 2011; 22:e75-e79.
• [27]Vidal C, Enrique E, Gonzalo A, Moreno C, Tabar AI, Expert Clinical Participants. Diagnosis and allergen immunotherapy treatment of polysensitised patients with respiratory allergy in Spain: an Allergists’ Consensus. Clin Transl Allergy. 2014;4:36. doi:10.1186/2045-7022-4-36
• [28]European Medicines Agency. Guideline on allergen products: production and quality issues. London; 2008 EMEA/CHMP/BWP/304831/2007. http://www. ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003333.pdf webcite
• [29]Lorenz AR, Lüttkopf D, May S, Scheurer S, Vieths S. The principle of homologous groups in regulatory affairs of allergen products—a proposal. Int Arch Allergy Immunol. 2009; 148:1-17.
• [30]Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I et al.. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011; 127 Suppl:S1-S55.
• [31]Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol. 2009; 123:763-769.
• [32]Calderon MA, Cox LS. Monoallergen sublingual immunotherapy versus multiallergen subcutaneous immunotherapy for allergic respiratory diseases: a debate during the AAAAI 2013 Annual Meeting in San Antonio, Texas. J Allergy Clin Immunol Pract. 2014; 2:136-143.
• [33]Bahceciler NN, Galip N, Cobanoglu N. Multi allergen-specific immunotherapy in polysensitized patients: where are we? Immunotherapy. 2013; 5:183-190.
• [34]Passalacqua G. The use of single versus multiple antigens in specific allergen immunotherapy for allergic rhinitis: review of the evidence. Curr Opin Allergy Clin Immunol. 2014; 14:20-24.
• [35]Pham-Thi N, Bousiquier P, Chartier A. Polysensibilisation aux pneumallergènes : étude des profils cliniques et des modalités de prescription d’immunothérapies. Quelle immunothérapie pour les patients polysensibilisés ? Résultats d’une enquête nationale des pratiques auprès des allergologues [Polysensitization to aeroallergens: Study of clinical profiles and immunotherapy modalities of prescription]. Revue Française d’Allergologie. 2012; 52:3-10.
• [36]Hadler M, Karagiannis E, Shah-Hosseini K, Mösges R. Effectiveness and tolerability of a 2-year sublingual allergen immunotherapy (AIT) in routine medical practice in birch pollen allergic patients. Italy: Poster presented at the European Academy of Allergy and Clinical Immunology and World Allergy Organization Congress 2013 in Milan; 2013.
• [37]Shah-Hosseini K, Mioc K, Hadler M, Karagiannis E, Mösges R. Optimum treatment strategies for polyallergic patients—analysis of a large observational trial. Curr Med Res Opin. 2015; 6:1-11.
• [38]Ciprandi G, Incorvaia C, Puccinelli P, Scurati S, Masieri S, Frati F. The POLISMAIL lesson: sublingual immunotherapy may be prescribed also in polysensitized patients. Int J Immunopathol Pharmacol. 2010; 23:637-640.
• [39]Ciprandi G, Cadario GD, Gioacchino M, Gangemi S, Gasparini A, Isola S et al.. Sublingual immunotherapy in children with allergic polysensitization. Allergy Asthma Proc. 2010; 31:227-231.
• [40]Ciprandi G, Incorvaia C, Puccinelli P, Soffia S, Scurati S, Frati F. Polysensitization as a challenge for the allergist: the suggestions provided by the polysensitization impact on allergen immunotherapy studies. Expert Opin Biol Ther. 2011; 11:715-722.
• [41]Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW et al.. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy. 2014; 69:854-867.
• [42]Haahtela T, Burbach GJ, Bachert C, Bindslev-Jensen C, Bonini S, Bousquet J et al.. Clinical relevance is associated with allergen-specific wheal size in skin prick testing. Clin Exp Allergy. 2014; 44:407-416.
• [43]Sastre J, Landivar ME, Ruiz-García M, Andregnette-Rosigno MV, Mahillo I. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy. 2012; 67(5):709-711.
• [44]Canonica GW, Ansotegui IJ, Pawankar R, Schmid-Grendelmeier P, van Hage M, Baena-Cagnani CE et al.. A WAO—ARIA—GA 2 LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J. 2013; 6(1):17. BioMed Central Full Text
• [45]Douladiris N, Savvatianos S, Roumpedaki I, Skevaki C, Mitsias D, Papadopoulos NG. A molecular diagnostic algorithm to guide pollen immunotherapy in southern Europe: towards component-resolved management of allergic diseases. Int Arch Allergy Immunol. 2013; 162(2):163-172.
• [46]Stringari G, Tripodi S, Caffarelli C, Dondi A, Asero R, Di Rienzo Businco A et al.. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol. 2014; 134(1):75-81.
• [47]Moreno C, Justicia JL, Quiralte J, Moreno-Ancillo A, Iglesias-Cadarso A, Torrecillas M et al.. Olive, grass or both? Molecular diagnosis for the allergen immunotherapy selection in polysensitized pollinic patients. Allergy. 2014; 69:1357-1363.
• [48]Darsow U, Brockow K, Pfab F, Jakob T, Petersson CJ, Borres MP et al.. Allergens. Heterogeneity of molecular sensitization profiles in grass pollen allergy–implications for immunotherapy? Clin Exp Allergy. 2014; 44(5):778-786.
• [49]Comite P, Minale P, Ferrero F, Mussap M, Ciprandi G. Der p 1 IgE measurement for distinguishing between sensitization and allergy. Immunol Lett. 2015; 166(2):145-146.
• [50]Ciprandi G, Comite P, Ferrero F, Minale P, Voltolini S, Bignardi D et al.. Can serum white birch (Betula verrucosa) pollen antigen (Bet v 1) immunoglobulin E measurement distinguish between sensitization and allergy? Int Forum Allergy Rhinol. 2015.
• [51]Ciprandi G, Alesina R, De Amici M. Serum specific IgE: biomarker for specific immunotherapy responsiveness? Allergol Immunopathol (Madr). 2014;42(4):369–71. doi:10.1016/j.aller.2012.12.004. (Epub 2013 Mar 6).
• [52]Tosca M, Silvestri M, Accogli A, Rossi GA, Ciprandi G. Serum-specific IgE and allergen immunotherapy in allergic children. Immunotherapy. 2014; 6(1):29-33.
• [53]Ciprandi G, Silvestri M. Serum specific IgE: a biomarker of response to allergen immunotherapy. J Investig Allergol Clin Immunol. 2014; 24(1):35-39.
• [54]Crobach MJ, Hermans J, Kaptein AA, Ridderikhoff J, Petri H, Mulder JD. The diagnosis of allergic rhinitis: how to combine the medical history with the results of radioallergosorbent tests and skin prick tests. Scand J Prim Health Care. 1998; 16(1):30-36.
• [55]Moingeon P. Progress in the development of specific immunotherapies for house dust mite allergies. Expert Rev Vaccines. 2014; 13:1463-1473.
• [56]Ciprandi G, Cadario G, Di Gioacchino M, Gangemi S, Minelli M, Ridolo E et al.. Sublingual immunotherapy in polysensitized allergic patients with rhinitis and/or asthma: allergist choices and treatment efficacy. J Biol Regul Homeost Agents. 2009; 23(3):165-171.
• [57]Ciprandi G, Cadario G, Valle C, Ridolo E, Verini M, Di Gioacchino M et al.. Sublingual immunotherapy in polysensitized patients: effect on quality of life. J Investig Allergol Clin Immunol. 2010; 20(4):274-279.
• [58]Bozek A, Kolodziejczyk K, Warkocka-Szoltysek B, Jarzab J. Grass pollen sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with seasonal allergic rhinitis. Am J Rhinol Allergy. 2014; 28:423-427.
• [59]Irani C, Saleh RA, Jammal M, Haddad F. High-dose sublingual immunotherapy in patients with uncontrolled allergic rhinitis sensitized to pollen: a real-life clinical study. Int Forum Allergy Rhinol. 2014; 4(10):802-807.
• [60]Malling HJ, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E et al.. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy. 2009; 39:387-393.
• [61]Nelson H, Blaiss M, Nolte H, Würtz SØ, Andersen JS, Durham SR. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy. 2013; 68(2):252-255.
• [62]Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract. 2013;1(3):228–41. doi:10.1016/j.jaip.2013.03.013. (Epub 2013 Apr 29).
• [63]Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database Syst Rev 2009;(3):CD005530.
• [64]Passalacqua G, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clin Exp Allergy. 2013; 43(1):22-28.
• [65]Reisacher WR, Visaya JM. Patient adherence to allergy immunotherapy. Curr Opin Otolaryngol Head Neck Surg. 2013; 21(3):256-262.
• [66]Kaul S, May S, Luttkopf D, Vieths S. Regulatory environment for allergen-specific immunotherapy. Allergy. 2011; 66:753-764.
• [67]Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P et al.. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases—S2k. Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014; 23:282-319.
• [68]Nony E, Bouley J, Le Mignon M, Lemoine P, Jain K, Horiot S et al.. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients. Allergy. 2015; 70:795-804.
• [69]Bachert C, Larché M, Bonini S, Canonica GW, Kündig T, Larenas-Linnemann D et al.. Allergen immunotherapy on the way to product-based evaluation—a WAO statement. World Allergy Organ J. 2015; 8:2. BioMed Central Full Text